Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Antonio Passaro

Showing results (1-10 of 144) with videos related to

Pageof 15
Sort By:
The New England Journal of Medicine|July 13, 2022
Setting the Benchmark for <i>KRAS</i> -Mutated NSCLCAntonio Passaro, Solange Peters
The New England Journal of Medicine|April 10, 2024
Adjuvant Alectinib in <i>ALK</i>-Rearranged NSCLC - Here and NowAntonio Passaro, Solange Peters
The New England Journal of Medicine|January 19, 2022
Targeting <i>HER2</i>-Mutant NSCLC - The Light Is OnAntonio Passaro, Solange Peters
Translational Lung Cancer Research|March 26, 2015
Neoadjuvant EGFR TKIs: toward personalized management in non-small-cell lung cancerAntonio Passaro, Enrico Cortesi
The Lancet. Oncology|January 15, 2026
Precision oncology in resected EGFR-mutant NSCLCAntonio Passaro, Xiuning Le
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 5, 2014
Afatinib-related nonhematologic adverse events: is common evaluation enough for now?Filippo de Marinis, Antonio Passaro
Translational Lung Cancer Research|February 11, 2020
Looking for the high way in EGFR-positive non-small cell lung cancer through the evaluation of survival endpointsAntonio Passaro, Filippo de Marinis
Translational Lung Cancer Research|May 22, 2018
Dacomitinib in EGFR-positive non-small cell lung cancer: an attractive but broken optionAntonio Passaro, Filippo de Marinis
Annals of Palliative Medicine|April 6, 2015
Expectations as outcome of effectiveness for patients with metastatic lung cancerAntonio Passaro, Filippo de Marinis
Recenti Progressi in Medicina|December 21, 2016
[Nivolumab in second-line treatment of squamous non-small cell lung cancer.]Filippo De Marinis, Antonio Passaro
Pageof 15

Showing results (1-10 of 144) with videos related to

Sort By:
Pageof 15
The New England Journal of Medicine|July 13, 2022
Setting the Benchmark for <i>KRAS</i> -Mutated NSCLCAntonio Passaro, Solange Peters
The New England Journal of Medicine|April 10, 2024
Adjuvant Alectinib in <i>ALK</i>-Rearranged NSCLC - Here and NowAntonio Passaro, Solange Peters
The New England Journal of Medicine|January 19, 2022
Targeting <i>HER2</i>-Mutant NSCLC - The Light Is OnAntonio Passaro, Solange Peters
Translational Lung Cancer Research|March 26, 2015
Neoadjuvant EGFR TKIs: toward personalized management in non-small-cell lung cancerAntonio Passaro, Enrico Cortesi
The Lancet. Oncology|January 15, 2026
Precision oncology in resected EGFR-mutant NSCLCAntonio Passaro, Xiuning Le
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 5, 2014
Afatinib-related nonhematologic adverse events: is common evaluation enough for now?Filippo de Marinis, Antonio Passaro
Translational Lung Cancer Research|February 11, 2020
Looking for the high way in EGFR-positive non-small cell lung cancer through the evaluation of survival endpointsAntonio Passaro, Filippo de Marinis
Translational Lung Cancer Research|May 22, 2018
Dacomitinib in EGFR-positive non-small cell lung cancer: an attractive but broken optionAntonio Passaro, Filippo de Marinis
Annals of Palliative Medicine|April 6, 2015
Expectations as outcome of effectiveness for patients with metastatic lung cancerAntonio Passaro, Filippo de Marinis
Recenti Progressi in Medicina|December 21, 2016
[Nivolumab in second-line treatment of squamous non-small cell lung cancer.]Filippo De Marinis, Antonio Passaro
Pageof 15